Abstract
Summary
The Middle East and Africa PCR-based infectious diseases market is expected to reach USD 765,557.03 thousand by 2031 from USD 547,663.09 thousand in 2023, growing with a CAGR of 4.5% in the forecast period of 2024 to 2031.
Market Segmentation
Middle East and Africa PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Other PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others), Country (South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) – Industry Trends and Forecast to 2031
Overview of Middle East and Africa PCR-based Infectious Diseases Market Dynamics
Driver
• Increasing PCR-based research activities
Restraint
• High cost of PCR test services
Opportunity
• Disease surveillance for early detection and monitoring of infectious diseases
Market Players
Some of the major market players operating in the Middle East and Africa PCR-based infectious diseases market are:
• DNA Labs India
• DrSafeHands
• Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
• Max Lab
• MicroGen Diagnostics
• pathlab
• The Washington Travel Clinic
• Clarewell Clinics
• AZOVA
• One Life Home Health Care Center
• LalPathLabs
Table of Contents
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET 19
1.4 CURRENCY AND PRICING 20
1.5 LIMITATIONS 21
1.6 MARKETS COVERED 21
2 MARKET SEGMENTATION 24
2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 DBMR TRIPOD DATA VALIDATION MODEL 27
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
2.6 MULTIVARIATE MODELLING 31
2.7 MARKET APPLICATION COVERAGE GRID 32
2.8 TEST TYPE LIFELINE CURVE 33
2.9 DBMR MARKET POSITION GRID 34
2.10 VENDOR SHARE ANALYSIS 35
2.11 SECONDARY SOURCES 36
2.12 ASSUMPTIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 40
4.1 PESTEL ANALYSIS 41
4.2 PORTER’S FIVE FORCES 42
5 MARKET OVERVIEW 43
5.1 DRIVERS 45
5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES 45
5.1.2 RISING CASES OF INFECTIOUS DISEASES 45
5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS 46
5.2 RESTRAINTS 47
5.2.1 HIGH COST OF PCR TEST SERVICES 47
5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 48
5.3 OPPORTUNITIES 49
5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES 49
5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY 49
5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS 50
5.4 CHALLENGES 51
5.4.1 DATA SECURITY AND PRIVACY CONCERNS 51
5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE 51
6 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE 53
6.1 OVERVIEW 54
6.2 TUBERCULOSIS PCR TEST 60
6.3 HEPATITIS PCR TEST 60
6.3.1 HEPATITIS C PCR TEST 61
6.3.2 HEPATITIS B PCR TEST 61
6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST 62
6.5 INFLUENZA PCR TEST 62
6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST 63
6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST 63
6.8 GONORRHEA PCR TEST 64
6.9 SALMONELLOSIS PCR TEST 64
6.10 ROTAVIRUS PCR TEST 65
6.11 BORDETELLA PCR TEST 65
6.12 H. PYLORI PCR TEST 66
6.13 SARS (COVID-19) PCR TEST 66
6.14 NOROVIRUS PCR TEST 67
6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST 67
6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST 68
6.17 ENTEROCOCCUS PCR TEST 68
6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST 69
6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST 69
6.20 OTHERS PCR TEST 70
7 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION 71
7.1 OVERVIEW 72
7.2 VIRAL INFECTION 75
7.2.1 SARS (COVID-19) INFECTION 75
7.2.2 ROTAVIRUS INFECTION 75
7.2.3 NOROVIRUS INFECTION 75
7.2.4 OTHERS 76
7.3 RESPIRATORY TRACT INFECTION 76
7.3.1 INFLUENZA 76
7.3.2 TUBERCULOSIS 76
7.3.3 BORDETELLA 77
7.4 SEXUALLY TRANSMITTED INFECTION 77
7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION 78
7.4.2 GONORRHEA 78
7.4.3 HEAPTITIS 78
7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 78
7.4.5 HUMAN PAPILLOMAVIRUS (HPV) 78
7.4.6 MYCOPLASMA GENITALIUM (MG) 78
7.4.7 OTHERS 78
7.5 HOSPITAL ACQUIRED INFECTIONS 79
7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) 79
7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE) 79
7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 80
7.5.4 OTHERS 80
7.6 OTHER INFECTIONS 80
7.6.1 SALMONELLOSIS 80
7.6.2 H. PYLORI 81
7.6.3 ENTEROCOCCUS INFECTIONS 81
7.6.4 OTHERS 81
8 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN 82
8.1 OVERVIEW 83
8.2 VIRAL 86
8.3 BACTERIAL 86
8.4 FUNGAL 87
8.5 PROTOZOA 87
8.6 OTHERS 88
9 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY 89
9.1 OVERVIEW 90
9.2 RT PCR 93
9.3 MULTIPLEX PCR 93
9.4 OTHERS 94
10 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE 95
10.1 OVERVIEW 96
10.2 GERIATRIC 99
10.3 PEDIATRIC 99
10.4 ADULTS 100
11 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING 101
11.1 OVERVIEW 102
11.2 LABORATORY BASED TESTING 105
11.3 POINT OF CARE TESTING 105
12 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER 106
12.1 OVERVIEW 107
12.2 DIAGNOSTIC CENTERS 110
12.3 HOSPITAL 110
12.4 CLINICS 111
12.5 COMMUNITY HEALTH CENTERS 111
12.6 ACADEMIC AND RESEARCH INSTITUTES 112
12.7 HOME HEALTHCARE 112
12.8 OTHERS 113
13 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION 114
13.1 MIDDLE EAST AND AFRICA 117
13.1.1 SOUTH AFRICA 126
13.1.2 U.A.E 134
13.1.3 SAUDI ARABIA 142
13.1.4 EGYPT 150
13.1.5 ISRAEL 158
13.1.6 REST OF MIDDLE EAST AND AFRICA 166
14 MIDDLE EAST AND AFRICA PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE 169
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 169
15 SWOT ANALYSIS 170
16 COMPANY PROFILE 171
16.1 MICROGEN DIAGNOSTICS 171
16.1.1 COMPANY SNAPSHOT 171
16.1.2 SERVICE PORTFOLIO 171
16.1.3 RECENT DEVELOPMENTS 172
16.2 MAX LAB 173
16.2.1 COMPANY SNAPSHOT 173
16.2.2 SERVICE PORTFOLIO 173
16.3 DNA LABS INDIA 175
16.3.1 COMPANY SNAPSHOT 175
16.3.2 SERVICE PORTFOLIO 175
16.3.3 RECENT DEVELOPMENT 176
16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD 177
16.4.1 COMPANY SNAPSHOT 177
16.4.2 SERVICE PORTFOLIO 177
16.4.3 RECENT DEVELOPMENT 178
16.5 LALPATHLABS 179
16.5.1 COMPANY SNAPSHOT 179
16.5.2 REVENUE ANALYSIS 179
16.5.3 PRODUCT PORTFOLIO 180
16.5.4 RECENT DEVELOPMENTS 180
16.6 AZOVA 181
16.6.1 COMPANY SNAPSHOT 181
16.6.2 PRODUCT PORTFOLIO 181
16.6.3 RECENT DEVELOPMENTS 181
16.7 CLAREWELL CLINICS 182
16.7.1 COMPANY SNAPSHOT 182
16.7.2 PRODUCT DESCRIPTION 182
16.7.3 RECENT DEVELOPMENTS 182
16.8 DRSAFEHANDS 183
16.8.1 COMPANY SNAPSHOT 183
16.8.2 SERVICE PORTFOLIO 183
16.8.3 RECENT DEVELOPMENT 183
16.9 ONE LIFE HOME HEALTH CARE CENTER 184
16.9.1 COMPANY SNAPSHOT 184
16.9.2 PRODUCT DESCRIPTION 184
16.9.3 RECENT DEVELOPMENTS 184
16.10 PATHLAB 185
16.10.1 COMPANY SNAPSHOT 185
16.10.2 SERVICE PORTFOLIO 185
16.10.3 RECENT DEVELOPMENT 185
16.11 THE WASHINGTON TRAVEL CLINIC 186
16.11.1 COMPANY SNAPSHOT 186
16.11.2 SERVICE PORTFOLIO 186
16.11.3 RECENT DEVELOPMENT 187
17 QUESTIONNAIRE 188
18 RELATED REPORTS 192